Liver cancer is the third leading cause of cancer-related deaths worldwide, posing a general threat to public health. Current therapies provide limiting survival rates, highlighting the need to develop alternative therapeutic approaches for the treatment of liver cancer. NAT10 promotes HCC oncogenesis and is a potential therapeutic target in liver cancer. The studies proposed here will advance our understanding of how NAT10 promotes HCC oncogenesis. This knowledge can be used to design and identify NAT10 inhibitors with high specificity and efficacy while reducing gross pleiotropic effects. Future studies will then be implemented to study the therapeutic benefits of inhibiting NAT10 in vivo and preclinical models of HCC.
|Effective start/end date||7/1/22 → 6/30/25|
- American Association for Cancer Research (22-20-01-ARAN)
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.